Tiziana Life Sciences Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLSA research report →
Price Chart
About the company
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression.
- CEO
- Ivor R. Elrifi
- IPO
- 2018
- Employees
- 10
- HQ
- London, GB
Get TickerSpark's AI analysis on TLSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $79.45M
- P/E
- -3.29
- PEG
- 0.05
- P/S
- 0.00
- P/B
- -31.45
- EV/EBITDA
- -3.39
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1869.09%
- ROIC
- 1284.85%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-21,132,000
- Net Income
- $-18,431,000-55.4%
- EPS
- $-0.16-45.5%
- OCF Growth
- -953.5%
- FCF Growth
- -942.3%
- 52W High
- $1.90
- 52W Low
- $0.55
- 50D MA
- $0.89
- 200D MA
- $1.15
- Beta
- 0.46
- RSI (14)
- 40
- Avg Volume
- 606.04K
No earnings-call transcripts are available for TLSA yet.
- Free Float
- 50.0%
- Shares Outstanding
- 128.03M
- Float Shares
- 64.08M
of shares held by institutions
34 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Marshall Wace, Llp | 1.18M | ▲ 1.18M |
| Dauntless Investment Group, LLC | 1.16M | ▼ 1.00M |
| Renaissance Technologies LLC | 500.13K | ▲ 487.03K |
| Zhang Financial LLC | 140.35K | ▲ 14.40K |
| Jane Street Group, LLC | 120.82K | ▲ 107.02K |
| Goldman Sachs Group Inc | 119.24K | ▲ 43.58K |
| Citadel Advisors LLC | 80.22K | ▲ 45.13K |
| Focus Partners Wealth | 79.36K | 0 |
| Hsbc Holdings PLC | 62.44K | 0 |
| Morgan Stanley | 53.66K | 0 |
| China Universal Asset Management Co., Ltd. | 50.00K | ▲ 32.00K |
| Ewa, LLC | 44.69K | ▼ 1.26K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 15, 26 | Elrifi Ivor | other | 1,050,000 |
| Aug 15, 26 | Elrifi Ivor | other | 1,050,000 |
| Jul 21, 26 | CERRONE GABRIELE M | buy | 42,357 |
| Jun 12, 26 | CERRONE GABRIELE M | buy | 15,000 |
| Aug 5, 26 | Elrifi Ivor | buy | 237,616 |
| Aug 4, 26 | Elrifi Ivor | buy | 83,807 |
| Aug 3, 26 | Elrifi Ivor | buy | 667,000 |
| Mar 18, 26 | Elrifi Ivor | other | 0 |
| Aug 15, 26 | Elrifi Ivor | other | 0 |
| Jul 21, 26 | CERRONE GABRIELE M | other | 42,357 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TLSA coverage
Recent articles, reports, and earnings notes.
No research on TLSA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TLSA report →Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcript
seekingalpha.com · Nov 9
Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab
globenewswire.com · Nov 9
Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results
globenewswire.com · Nov 5
Tiziana's experimental MS treatment meets main goals in mid-stage study
reuters.com · Nov 2
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
globenewswire.com · Oct 21
Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab
proactiveinvestors.com · Oct 16
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease
globenewswire.com · Oct 16
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
proactiveinvestors.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.